Alpha Tau Medical Ltd. (DRTS)
2.95
-0.07 (-2.32%)
At close: Mar 03, 2025, 12:01 PM
No 1D chart data available
| Bid | 2.97 |
| Market Cap | 206.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.71M |
| EPS (ttm) | -0.43 |
| PE Ratio (ttm) | -6.86 |
| Forward PE | -8.27 |
| Analyst | Buy |
| Ask | 3 |
| Volume | 14,528 |
| Avg. Volume (20D) | 96,315 |
| Open | 3.00 |
| Previous Close | 3.02 |
| Day's Range | 2.94 - 3.04 |
| 52-Week Range | 1.75 - 4.39 |
| Beta | 0.84 |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and othe...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 8, 2021
Employees 121
Stock Exchange NASDAQ
Ticker Symbol DRTS
Website https://www.alphatau.com
Analyst Forecast
According to 2 analyst ratings, the average rating for DRTS stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 171.37% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 years ago · stockmarket.com
4 Top Biotech Stocks To Watch TodayAs the industry continues to make new discoveries, could biotech stocks be in focus?
